Greenwich LifeSciences ( (GLSI) ) has released a notification of late filing.
Greenwich LifeSciences, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for this delay is the significant increase in research and development expenses, which rose by approximately 68% due to clinical trial costs and an options grant vesting. The company expects to file the report by April 15, 2025, within the allowed extension period. Financially, the company anticipates a notable change in its earnings statements, with increased expenses impacting the results. Greenwich LifeSciences is actively working on compliance, with the notification signed by CEO Snehal Patel.
More about Greenwich LifeSciences
YTD Price Performance: -12.95%
Average Trading Volume: 32,517
Technical Sentiment Signal: Buy
Current Market Cap: $134.3M
Find detailed analytics on GLSI stock on TipRanks’ Stock Analysis page.